Published in Thromb Haemost on October 01, 1994
A prospective study of human immunodeficiency virus type 1 infection and the development of AIDS in subjects with hemophilia. N Engl J Med (1989) 4.04
Essential role of LAT in T cell development. Immunity (1999) 3.94
Definitions in hemophilia. Recommendation of the scientific subcommittee on factor VIII and factor IX of the scientific and standardization committee of the International Society on Thrombosis and Haemostasis. Thromb Haemost (2001) 3.13
Serological markers in early stages of human immunodeficiency virus infection in haemophiliacs. Lancet (1986) 2.92
Factor VIII:C inhibitor associated with monoclonal-antibody purified FVIII concentrate. Lancet (1990) 2.91
Comparison of dosage schedules of rt-PA in the treatment of proximal deep vein thrombosis. J Lab Clin Med (1992) 2.22
Long-term evaluation of HIV antigen and antibodies to p24 and gp41 in patients with hemophilia. Potential clinical importance. N Engl J Med (1987) 2.18
Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates. Blood (2001) 1.99
Intracranial and extracranial hemorrhages in newborns with hemophilia: a review of the literature. J Pediatr Hematol Oncol (1999) 1.88
The safety and efficacy of B-domain deleted recombinant factor VIII concentrate in patients with severe haemophilia A. Haemophilia (2003) 1.80
Use of recombinant factor VIIa in 3 patients with inherited type I Glanzmann's thrombasthenia undergoing invasive procedures. Thromb Haemost (2000) 1.71
Acquired inhibitors. Baillieres Clin Haematol (1996) 1.62
D-dimer, factor VIII coagulant activity, low-intensity warfarin and the risk of recurrent venous thromboembolism. J Thromb Haemost (2006) 1.62
Treatment of inherited coagulation disorders. Am J Med (1995) 1.60
Factor VIII gene inversions in severe hemophilia A: results of an international consortium study. Blood (1995) 1.59
Splenectomy is safe and effective in human immunodeficiency virus-related immune thrombocytopenia. Blood (1993) 1.55
von Willebrand factor interacts with malignant hematopoietic cell lines: evidence for the presence of specific binding sites and modification of von Willebrand factor structure and function. J Lab Clin Med (1992) 1.54
PFA-100 system: a new method for assessment of platelet dysfunction. Semin Thromb Hemost (1998) 1.48
Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Thromb Haemost (1998) 1.35
Factor IX inhibitors and anaphylaxis in hemophilia B. J Pediatr Hematol Oncol (1997) 1.34
Circulating coagulation inhibitors in the acquired immunodeficiency syndrome. Ann Intern Med (1986) 1.32
Haemophilia B due to a de novo insertion of a human-specific Alu subfamily member within the coding region of the factor IX gene. Eur J Hum Genet (1993) 1.24
Randomised controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of acute pulmonary embolism. Lancet (1988) 1.24
Automated dithionite test for rapid, inexpensive detection of hemoglobin S and non-S sickling hemoglobinopathies. Clin Chem (1971) 1.24
Health care expenditures for Medicaid-covered males with haemophilia in the United States, 2008. Haemophilia (2011) 1.21
Inhibitors in factor IX deficiency a report of the ISTH-SSC international FIX inhibitor registry (1997-2006). Haemophilia (2009) 1.19
Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry. Haemophilia (2005) 1.18
Healthcare expenditures for males with haemophilia and employer-sponsored insurance in the United States, 2008. Haemophilia (2011) 1.17
Efficacy of prothrombin-complex concentrates in hemophiliacs with antibodies to factor VIII: a multicenter therapeutic trial. N Engl J Med (1980) 1.16
Risks of immunodeficiency, AIDS, and death related to purity of factor VIII concentrate. Multicenter Hemophilia Cohort Study. Lancet (1994) 1.16
A prospective study of treatment of acquired (autoimmune) factor VIII inhibitors with high-dose intravenous gammaglobulin. Blood (1995) 1.11
In vitro correlation of platelet aggregation with occurrence of disseminated intravascular coagulation and subacute bacterial endocarditis. J Lab Clin Med (1987) 1.10
Factor VIII alloantibody inhibitors: cost analysis of immune tolerance induction vs. prophylaxis and on-demand with bypass treatment. Haemophilia (2015) 1.09
Anaphylactic response to factor IX replacement therapy in haemophilia B patients: complete gene deletions confer the highest risk. Haemophilia (1999) 1.08
Dithionite tube test--a rapid, inexpensive technique for the detection of hemoglobin S and non-S sickling hemoglobin. Clin Chem (1971) 1.08
Idiopathic thrombocytopenic purpura in childhood. J Pediatr (1966) 1.07
B-domain deleted recombinant factor VIII preparations are bioequivalent to a monoclonal antibody purified plasma-derived factor VIII concentrate: a randomized, three-way crossover study. Haemophilia (2005) 1.07
Acute pulmonary embolism treated with tissue plasminogen activator. Lancet (1986) 1.06
Phenotypic expressions of CCR5-delta32/delta32 homozygosity. J Acquir Immune Defic Syndr (1999) 1.05
Suppressor cell function after intravenous gammaglobulin treatment in adult chronic idiopathic thrombocytopenic purpura. Br J Haematol (1985) 1.05
HIV infection in sexual partners of HIV-seropositive patients with hemophilia. N Engl J Med (1989) 1.04
Low CD4+ counts in a study of transfusion safety. The Transfusion Safety Study Group. N Engl J Med (1993) 1.02
Microwave technology for the rapid thawing of frozen blood components. Am J Clin Pathol (1985) 1.00
Development of anaphylactic shock in haemophilia B patients with inhibitors. Blood Coagul Fibrinolysis (1998) 0.98
Variability in serial CD4 counts and relation to progression of HIV-I infection to AIDS in haemophilic patients. Transfusion Safety Study Group. BMJ (1992) 0.98
Oral urea and the prophylactic treatment of sickle cell disease--a preliminary report. Am J Med Sci (1971) 0.98
Idiopathic thrombocytopenic purpura in children. Semin Thromb Hemost (1977) 0.97
Anti-s hemolytic disease: a case report. Transfusion (1967) 0.97
Abnormal T-lymphocyte subpopulations associated with transfusion of blood-derived products. Lancet (1983) 0.96
Neurological complications of sickle cell anemia. Am J Pediatr Hematol Oncol (1982) 0.96
Incidence of lymphomas and other cancers in HIV-infected and HIV-uninfected patients with hemophilia. JAMA (1992) 0.95
Survey of current prophylaxis practices and bleeding characteristics of children with severe haemophilia A in US haemophilia treatment centres. Haemophilia (2011) 0.94
DDAVP: does the drug have a direct effect on the vessel wall? Thromb Res (1983) 0.94
The use of porcine factor VIII concentrate (Hyate:C) in the treatment of patients with inhibitor antibodies to factor VIII. A multicenter US experience. Arch Intern Med (1989) 0.94
Warfarin anticoagulation: difficulties in interpretation of the prothrombin time. Thromb Res (1982) 0.92
Haemophilia A: two cases showing unusual features at birth. Haemophilia (1998) 0.92
The incidence of development of irregular red cell antibodies in patients with sickle cell anemia. Transfusion (1986) 0.92
Pharmacokinetics and safety of OBI-1, a recombinant B domain-deleted porcine factor VIII, in subjects with haemophilia A. Haemophilia (2012) 0.91
Sickle cell crisis terminated by intravenous urea in sugar solutions--a preliminary report. Am J Med Sci (1971) 0.91
French previously untreated patients with severe hemophilia A after exposure to recombinant factor VIII : incidence of inhibitor and evaluation of immune tolerance. Thromb Haemost (1998) 0.90
Idiopathic thrombocytopenic purpura in children. The case for management without corticosteroids. Am J Pediatr Hematol Oncol (1984) 0.90
Recombinant tissue-type plasminogen activator versus a novel dosing regimen of urokinase in acute pulmonary embolism: a randomized controlled multicenter trial. J Am Coll Cardiol (1992) 0.90
Liver biopsy in patients with inherited disorders of coagulation and chronic hepatitis C. Haemophilia (2004) 0.90
Intravenous gamma globulin treatment for chronic idiopathic thrombocytopenic purpura in children. Am J Med (1984) 0.89
Congenital disorders affecting platelets. Semin Thromb Hemost (1977) 0.89
The prevalence of antibody to HTLV-I/II in United States plasma donors and in United States and French hemophiliacs. Transfusion (1990) 0.89
Monitoring of specific antibodies to human immunodeficiency virus structural proteins: clinical significance. Blood (1991) 0.89
A prophylactic transfusion program for children with sickle cell anemia complicated by CNS infarction. Am J Hematol (1976) 0.89
Cardiovascular comorbidities are increased in U.S. patients with haemophilia A: a retrospective database analysis. Haemophilia (2013) 0.88
Thymosin in the early diagnosis and treatment of high risk homosexuals and hemophiliacs with AIDS-like immune dysfunction. Ann N Y Acad Sci (1984) 0.88
D-dimer testing: the role of the clinical laboratory in the diagnosis of pulmonary embolism. J Clin Pathol (2001) 0.88
Quantitation of venous clot lysis with the D-dimer immunoassay during fibrinolytic therapy requires correction for soluble fibrin degradation. Circulation (1990) 0.87
Methylene blue for neutralization of heparin. Thromb Res (1989) 0.86
Progression to AIDS in French haemophiliacs: association with HLA-B35. AIDS (1993) 0.86
The overall effectiveness of prophylaxis in severe haemophilia. Haemophilia (2003) 0.86
Randomized double-blind, placebo-controlled trial of twice-daily zidovudine in asymptomatic haemophiliacs infected with the human immunodeficiency virus type 1. European-Australian Haemophilia Collaborative Study Group. Br J Haematol (1994) 0.86
Coagulant proteins and thrombin generation in synovial fluid: a model for extravascular coagulation. Am J Hematol (1995) 0.85
Open heart surgery in a hemophiliac patient. Hematologic management. Am J Dis Child (1974) 0.85
Uncontrolled thrombocytosis in chronic myeloproliferative disorders. Br J Haematol (1982) 0.85
Preoperative exchange transfusion in sickle cell anemia. J Pediatr Surg (1981) 0.85
Epidemiology and general guidelines of the management of acquired haemophilia and von Willebrand syndrome. Haemophilia (2008) 0.85
Hemophilia A in chromosomal female subjects. J Pediatr (1969) 0.85
Hemostatic responses to maximal exercise in oral contraceptive users. Am J Obstet Gynecol (1999) 0.84
Induction of immune tolerance in patients with hemophilia A and inhibitors treated with porcine VIIIC by home therapy. Blood (1990) 0.84
Recent evolution of clotting factor concentrates for hemophilia A and B. Transfusion Practices Committee. Transfusion (1993) 0.84
Stimulation of fibrinogen synthesis: a possible functional role of fibrinogen degradation products. Blood (1980) 0.84
Inverse correlation between age related abnormalities of T-cell immunity and circulating thymosin alpha 1 levels in haemophilia A. Br J Haematol (1984) 0.84
Pharmacokinetics of von Willebrand factor and factor VIIIC in patients with severe von Willebrand disease (type 3 VWD): estimation of the rate of factor VIIIC synthesis. Cooperative Study Groups. Br J Haematol (1996) 0.84
Assessment by gene amplification and serological markers of transmission of HIV-1 from hemophiliacs to their sexual partners and secondarily to their children. J Acquir Immune Defic Syndr (1990) 0.84
Inhibition of CD40 ligand (CD154) in the treatment of factor VIII inhibitors. Haematologica (2000) 0.83
The May-Hegglin anomaly: platelet function, ultrastructure and chromosome studies. Blood (1968) 0.83
Childhood idiopathic thrombocytopenic purpura. Am J Dis Child (1977) 0.83
Structural physiology of the human spleen. Am J Pediatr Hematol Oncol (1979) 0.83
Ultrastructural markers in circulating lymphocytes of subjects at risk for AIDS. Am J Clin Pathol (1985) 0.83
DDAVP: a useful alternative to blood components in moderate hemophilia A and von Willebrand disease. J Pediatr (1983) 0.83
Butaclamol hydrochloride (AY-23,028): an early evaluation in severely ill schizophrenics. Dis Nerv Syst (1975) 0.83